Adverse Drug Reactions

Selected news for the healthcare topic - Adverse Drug Reactions, collected since 10/2017. There are 1.4K items in the archive. This healthcare topic shares news with COVID-19, COVID-19 Vaccine, Bristol-Myers Squibb, Bristol-Myers and dozens of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
5/19/2022 Cocaine-induced rhabdomyolysis and compartment syndrome BMJ Case Reports: Adverse drug reactions and complications Cocaine-induced rhabdomyolysis and compartment syndrome Mian Harris Iftikhar 1 , 1 Internal Medicine , Hartford Hospital , Hartford , Connecticut , USA 2 Internal Medicine , St Francis Hospital , Hartford , Connecticut , USA 3 Pulmonary, Critical Care, and Sleep Medicine , Hartford Hospital , Hartford , Connecticut , USA Correspondence to Dr Mian Harris Iftikhar; harisiftikhar.biz(at)gmail.com Abstract A man in his 30s with a history of cocaine and intranasal heroin use ...
5/19/2022 Delivering Cost-Effective Genomics for Precision Medicine | by Intel | Intel Tech | May, 2022 | Medium Medium ... Scalable processor (formerly codenamed Sapphire Rapids). It is designed to scale on multicore systems to achieve best-in-class performance whether the clinical requirement is fast turnaround (e.g., in the emergency department to predict adverse drug reactions from a single patient genome) or high throughput (e.g., in an oncology lab to analyze multiple samples from the same tumor or from different patients).The Sentieon software is vectorized for modern processors ...
5/18/2022 Pharmacovigilance Market Size Worth USD 14.95 Billion by Globe Newswire ... szie of USD 14.95 billion during the forecast period (2021-2028).Market Scope:Pharmacovigilance is a pharmaceutical industry disciplined innovation. This is an unavoidable aspect of drug development and processing. It identifies risk factors for adverse drug reactions (ADRs), and pharmacovigilance pharmacists ensure that medications are used safely and appropriately. It also encourages the discovery of previously undiscovered ADRs and their interactions with existing ADRs.Get Free Sample PDF Brochure @ https ...
5/16/2022 iGenomeDx Inc. Wins 2022 SBA District Minority-Owned Small Business of the Year Business Wire ... to guide physicians to the most effective medication among the choices available based on an individual’s genetic makeup, effectively personalizing medicine. Such technology will help avoid trial and error, reduce hospitalizations due to adverse drug reactions , and reduce the cost of healthcare.“We are absolutely honored to receive this award,” commented Dr. Vanee, CEO of iGenomeDx.iGenomeDx continuously expanding its scope of providing cutting-edge testing to the ...
5/16/2022 iGenomeDx Inc. Wins 2022 SBA District Minority-Owned Small Business of the Year Yahoo News ... to guide physicians to the most effective medication among the choices available based on an individual’s genetic makeup, effectively personalizing medicine. Such technology will help avoid trial and error, reduce hospitalizations due to adverse drug reactions , and reduce the cost of healthcare."We are absolutely honored to receive this award," commented Dr. Vanee, CEO of iGenomeDx.iGenomeDx continuously expanding its scope of providing cutting-edge testing to the community ...
5/14/2022 Dapagliflozin efficacious and safe in treating heart failure Physicians Weekly ... patients with HF. However, there is a gap in knowledge as to whether new HF treatments are effective and safe in frail patients, as frail patients may have reduced tolerance to treatments, experience more adverse drug reactions , have poorer adherence, and be more likely to discontinue treatment than non-frail patients. This study demonstrated the efficacy and safety of dapagliflozin in patients with heart failure with reduced ejection fraction, regardless ...
5/13/2022 GenXys, Changing the Face of Clinical Decision Support Software, Wins MedTech Breakthrough Award PR Newswire ... the 2022 Best Overall Medical Data Solution Provider by MedTech Breakthrough Awards , which recognizes the top companies, people, platforms, and products in the health, fitness, and medical technology industries.In the US, 46 million adverse drug reactions (ADRs) are reported each year, leading to 1.3 million emergency room visits and a cost of billions to the healthcare system. When it comes to medications, one size doesn't fit all.GenXys' unique ...
5/11/2022 Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine BMJ PDF Case Reports: Adverse drug reactions and complications Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine 1 Ruppiner Kliniken , Neuruppin , Brandenburg , Germany 2 Anesthesia and intensive care , Unikliniken Ruppin-Brandenburg , Neuruppin , Germany Correspondence to Dr Mohammed Elkoumy; m.elkoumy(at)ukrb.de Abstract Since the start of vaccination against COVID-19 viral infection using adenovirus-based vector vaccine (eg, The Oxford ...
5/10/2022 Pharmacovigilance Market Set To Hit $15,259.8 Million Value by 2030, says P&S Intelligence PR Newswire ... therapeutic area, the oncology category held a 27% share. Due to the side-effects of cancer drugs, monitoring their safety is extremely important. In this regard, pharmacovigilance aids in detecting, managing, and even preventing adverse drug reactions and limiting the requirement for needless medical prescriptions.The high patient compliance for drug usage, rising concerns regarding drug safety, and growing incidence of toxicity and ADRs propel the pharmacovigilance market growth. Moreover ...
5/6/2022 Acute liver failure secondary to therapeutic paracetamol dosing in an extremely preterm neonate BMJ Case Reports: Adverse drug reactions and complications Acute liver failure secondary to therapeutic paracetamol dosing in an extremely preterm neonate Mary Judith Berry 1 , 2 , 3 1 Department of Paediatrics and Child Health , University of Otago , Wellington , New Zealand 2 Neonatal Intensive Care Unit , Wellington Regional Hospital , Wellington , New Zealand 3 Centre for Translational Physiology , University of Otago , Wellington , New Zealand Correspondence to Dr Krishna Raghu; krishna.raghu(at)ccdhb.org.nz Abstract ...
5/5/2022 Global Companion Diagnostics Market Report 2022: A $6.8 Billion Market by 2028 - Outlook, Opportunity and Demand Analysis, Market Forecasts - ResearchAndMarkets.com Yahoo News ... to 2028.The growth of the worldwide companion diagnostics market is often attributed to the rising specialization in personalized medicine and, therefore, the co-development of drug and diagnostic technologies. Additionally, rising cases of adverse drug reactions related to drugs, due to their lack of efficacy, drive the need for companion diagnostics.The growing need for targeted therapy will drive market growth.With advances in genetic sequencing and genomics, it ...
5/5/2022 Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases Nature ... association between finasteride and PD-related clinical features. The Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was queried to identify the ten drugs which were associated the most with the adverse drug reactions (ADRs) recorded as “penile curvature” and/or “Peyronie’s disease”. A similar analysis, including the same drugs, was carried out for the EMA (European Medicines Agency) EudraVigilance (EV) database. Descriptive data ...
5/4/2022 Global Pharmacovigilance Market Size & Trends Predicted to Reach USD 15.84 Billion by 2030, at 10.2% CAGR: Polaris Market Research PR Newswire ... pharmacovigilance-market/request-for-discount-pricingPharmacovigilance Market: Driving FactorsThe pharmacovigilance market is expected to grow at a favorable rate owing to the growing consumption and developments of drugs, the rising number of adverse drug reactions and toxicity, and the growing trend of outsourcing pharmacovigilance services. Also, surging demand for contract outsourcing and in-house pharmacovigilance is the key factor anticipated to fuel the market growth. Another contributor to ...
5/4/2022 Global Pharmacovigilance Market Size & Trends Predicted to Reach USD 15.84 Billion by 2030, at 10.2% CAGR: Polaris Market Research PR Newswire ... pharmacovigilance-market/request-for-discount-pricingPharmacovigilance Market: Driving FactorsThe pharmacovigilance market is expected to grow at a favorable rate owing to the growing consumption and developments of drugs, the rising number of adverse drug reactions and toxicity, and the growing trend of outsourcing pharmacovigilance services. Also, surging demand for contract outsourcing and in-house pharmacovigilance is the key factor anticipated to fuel the market growth. Another contributor to ...
5/2/2022 Pharmacogenomics Market To Cross $10,505.3 Million Value by 2030, says P&S Intelligence PR Newswire ... to reach $10,505.3 million , rising at a CAGR of 7.4% from 2021 to 2030, according to P&S Intelligence. The growing use of pharmacogenomics in the development and discovery of medicines, increasing rate of adverse drug reactions (ADRs), shift from reactive to preventive care, and growing prevalence of cancers and infectious diseases are the key drivers for market growth.Therefore, key players are extensively involved in seeking approvals and product ...
5/2/2022 Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience biomedcentral.com Research article- Open Access- Published:]Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience 118 (2022) [Cite this articleAbstractBackgroundSmartphone technology can support paperless reporting of adverse drug reactions (ADRs). The aims of this study were to systematically assess smartphone ADR-reporting applications, understand their qualitative and quantitative impact on ADR reporting, and garner key lessons from owners and developers.MethodsThis ...
5/2/2022 Pharmacogenomics Market To Cross $10,505.3 Million Value by 2030, says P&S Intelligence Yahoo News ... to reach $10,505.3 million , rising at a CAGR of 7.4% from 2021 to 2030, according to P&S Intelligence. The growing use of pharmacogenomics in the development and discovery of medicines, increasing rate of adverse drug reactions (ADRs), shift from reactive to preventive care, and growing prevalence of cancers and infectious diseases are the key drivers for market growth.P&S Intelligence Logo Therefore, key players are extensively involved in ...
5/2/2022 Pharmacogenomics Market To Cross $10,505.3 Million Value by 2030, says P&S Intelligence Yahoo News ... to reach $10,505.3 million , rising at a CAGR of 7.4% from 2021 to 2030, according to P&S Intelligence. The growing use of pharmacogenomics in the development and discovery of medicines, increasing rate of adverse drug reactions (ADRs), shift from reactive to preventive care, and growing prevalence of cancers and infectious diseases are the key drivers for market growth.P&S Intelligence Logo Therefore, key players are extensively involved in ...
5/1/2022 Rezolute Announces Positive Data from its Phase 2b (RIZE) Globe Newswire Highly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses‚â•50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug reactions or clinically significant hyperglycemia Study exceeded expectations for correction of hypoglycemia across multiple metrics, including hypoglycemia events and time in hypoglycemia Predictable and dose-dependent exposures with a clear dose-response Good safety and tolerability across all doses with no study ...
5/1/2022 Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism onenewspage.com ... the Pediatric Endocrine Society’s 2022 Annual Meeting· Highly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses· ≥50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug reactions or clinically significant hyperglycemia· Study exceeded expectations for correction of hypoglycemia across multiple metrics, including hypoglycemia events and time in hypoglycemia· Predictable and dose-dependent exposures with a clear dose-response· Good safety ...